Streetbeat News

Analyst Ratings

YMAB

Canaccord Genuity analyst William Plovanic has reiterated a Buy rating on Y-mAbs Therapeutics (NASDAQ:YMAB) and maintained a $21 price target.

Portfolio Pulse from richadhand@benzinga.com

June 07, 2023 | 2:35 pm

IRTC

Canaccord Genuity analyst William Plovanic has reiterated a Buy rating on iRhythm Technologies (NASDAQ:IRTC) and maintained a $153 price target.

Portfolio Pulse from richadhand@benzinga.com

June 07, 2023 | 2:33 pm

DT

Canaccord Genuity analyst Kingsley Crane has reiterated a Buy rating on Dynatrace (NYSE:DT) and maintained a $53 price target.

Portfolio Pulse from richadhand@benzinga.com

June 07, 2023 | 2:32 pm

BABA

A large bearish position on Alibaba Group Holding (NYSE:BABA) has been spotted, with 69% of big-money traders being bearish. Whales have been targeting a price range of $75 to $100 for BABA over the last 3 months. Several experts maintain Buy or Outperform ratings with price targets ranging from $115 to $145.

Portfolio Pulse from Benzinga Insights

June 07, 2023 | 2:32 pm

DOCS

Canaccord Genuity analyst Richard Close has reiterated a Buy rating on Doximity (NYSE:DOCS) and maintained a $40 price target.

Portfolio Pulse from richadhand@benzinga.com

June 07, 2023 | 2:32 pm

COIN

Canaccord Genuity analyst Joseph Vafi reinstated a Buy rating on Coinbase Global (NASDAQ:COIN) and maintained a $70 price target.

Portfolio Pulse from richadhand@benzinga.com

June 07, 2023 | 2:31 pm

BRZE

Canaccord Genuity analyst David Hynes reiterated a Buy rating on Braze (NASDAQ:BRZE) and maintained a $38 price target.

Portfolio Pulse from richadhand@benzinga.com

June 07, 2023 | 2:30 pm

NVCR

Piper Sandler analyst Jason Bednar maintains a Neutral rating on NovoCure (NASDAQ:NVCR) and lowers the price target from $67 to $62.

Portfolio Pulse from richadhand@benzinga.com

June 07, 2023 | 2:14 pm

GIII

Piper Sandler analyst Edward Yruma maintains a Neutral rating on G-III Apparel Group (NASDAQ:GIII) and raises the price target from $16 to $17.

Portfolio Pulse from richadhand@benzinga.com

June 07, 2023 | 2:12 pm

APTO

Piper Sandler analyst Edward Tenthoff maintains an Overweight rating on Aptose Biosciences (NASDAQ:APTO) but lowers the price target from $45 to $37.

Portfolio Pulse from richadhand@benzinga.com

June 07, 2023 | 2:11 pm